Intensification by high-dose cytarabine in postremission or induction therapy and prolonged maintenance are established strategies to improve the outcome in patients with acute myeloid leukemia (AML). Whether additional intensification can add to this effect has not yet been determined.
INTRODUCTION
Dose-response effects in both induction and postremission therapy have been reported from randomized multicenter trials. First, in postremission therapy, a prolonged monthly myelosuppressive maintenance after an induction-type consolidation produced a superior relapse-free survival (RFS) compared with consolidation and no maintenance. 1 In a later trial, myelosuppressive maintenance also proved superior to one course of high-dose cytarabine/mitoxantrone instead of maintenance. 2 The Cancer and Leukemia Group B compared postremission therapy with four courses of cytarabine 3 g/m 2 for six single doses, 400 mg/m 2 for five doses, or 100 mg/m 2 for five doses, and found a dose dependency in the RFS and survival (SV) of patients younger than age 60. 3 Similarly, in the remission induction therapy, a high-dose cytarabine combination improved the RFS versus that from a standard-dose combination. 4, 5 Introduced by the German Acute Myeloid Leukemia Cooperative Group, the strategy of doubleinduction also attempted an improvement in quality and duration of remission. 6 A version incorporating one course of high-dose cytarabine and mitoxantrone (HAM) 7 was associated with a longer overall survival (OS) in patients with poor prognostic features. 6 In our trial, the German Acute Myeloid Leukemia Cooperative Group investigated an additional intensification of double induction: two courses of HAM and an intensification of the postremission regimen by myeloablative chemotherapy and autologous stem-cell transplantation (SCT).
To compare treatment effects prospectively in prognostic subgroups, all random assignment was done upfront in one step and patients were stratified for prognostic features such as de novo acute myeloid leukemia (AML)/secondary AML/myelodysplastic syndrome (MDS), age, lactate dehydrogenase (LDH), WBC, and cytogenetic groups.
PATIENTS AND METHODS

Patients
Patients Ն 16 years of age with AML by common classification 8,9 who had never received antileukemic therapy were eligible, including de novo AML, AML secondary to myelodysplasia or other antecedent hematologic disorder, and AML secondary to treatment with cytotoxic drugs or radiotherapy. According to the WHO criteria, AML was defined as the presence of 20% or more blasts in the blood or bone marrow. 10, 11 In addition to overt AML, also high-risk MDS 12 with 11% to 19% bone marrow blasts was included in the trial. Patients with promyelocytic leukemia and translocation t(15;17) were excluded and treated in a separate trial. 13 Patients with another active cancer or a severe organ failure not explained by leukemia were not eligible. The trial was approved by the ethics committees of the participating centers and was conducted in accordance with the Declaration of Helsinki. A written informed consent was provided by all participants. Abbreviations: TAD, thioguanine, cytarabine, and daunorubicin; HAM, high-dose cytarabine and mitoxantrone; SCT, stem-cell transplantation; LDH, lactate dehydrogenase; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.
‫ء‬
In the total of 1,770 patients, the median age was 60 years (range, 16 to 85 years) and 52% were age Ն 60 years. †Favorable karyotypes included t(8;21)(q22;22), inv(16)(p13q22), or t(16;16)(p13;q22). Unfavorable karyotypes included losses or deletions of chromosomes 5 or 7 (Ϫ5, 5qϪ,Ϫ7, 7qϪ), chromosome 3(q21q26) abnormalities, abnormal chromosome 11(q23), or complex aberrant karyotypes with at least three structural and/or numerical abnormalities. Intermediate karyotypes were defined by normal karyotype or abnormalities not considered favorable or unfavorable.
‡Between TAD-HAM and HAM-HAM, P Ͻ .001 §A total of 74% of the patients had de novo AML, 17% had AML emerging from MDS, 6% had treatment-related AML and 3% had high-risk MDS. 
Prognostic Factors
In earlier analyses 2,6,14-16 age, cytogenetics, serum LDH, and residual bone marrow blasts 1 week after the first induction course were substantiated as independent prognostic factors. Cytogenetic groups were defined in accordance with results from other studies ( Table 1) .
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Study Design and Treatment
Before treatment started, all patients were randomly assigned upfront to one of the two induction therapies (thioguanine, cytarabine, and daunorubicin [TAD] -HAM or HAM-HAM), and in the same step patients younger than age 60 were randomly assigned for postremission therapy by either prolonged maintenance or by autologous SCT. The two randomizations were balanced against each other and were also balanced for the prognostic categories age Յ or older than 60 years; LDH Յ or more than 700 U/L; de novo AML/secondary AML plus MDS; and favorable, intermediate, or unfavorable karyotype. Given that cytogenetic analyses were not available at treatment start, this factor was only effective as a stratum for the postremission random assignment.
The TAD regimen for induction consisted of cytarabine 100 mg/m 2 /d by continuous intravenous (IV) infusion on days 1 and 2 and via 30-min IV infusions every 12 hours on days 3 to 8; daunorubicin 60 mg/m 2 via 60-minute IV infusions on days 3, 4, and 5; and thioguanine 100 mg/m 2 orally every 12 hours on days 3 to 9. The HAM induction regimen combined cytarabine 3 g/m 2 (in patients younger than 60 years) or 1 g/m 2 (in patients Ն 60 years) via 3-hour IV infusions every 12 hours on days 1 to 3, with mitoxantrone 10 mg/m 2 via 60-minute IV infusions on days 3 to 5. One week after the first induction course, a bone marrow aspirate was examined. A second induction course was administered to all patients younger than 60 years in any case, and in patients Ն 60 years if 5% or more residual blasts appeared in their bone marrow.
After achieving complete remission by bone marrow and peripheral blood criteria, 21 all patients received consolidation with one course identical to the TAD induction regimen. For maintenance treatment, patients were administered monthly courses of cytarabine 100 mg/m 2 every 12 hours by subcutaneous injections on days 1 to 5, and as a second agent from course to course, daunorubicin 45 mg/m 2 via 60-minute IV infusions on days 3 and 4, thioguanine 100 mg/m 2 orally every 12 hours on days 1 to 5, or cyclophosphamide 1 g/m 2 by IV injection on day 3, with the second agent changing in a rotating sequence. In patients age Ն 60 years, dosages of TAD 22 and maintenance courses were the same as those in younger patients.
Maintenance continued for 3 years, and dose reductions by 50% were made after critical nadirs in absolute neutrophils of less than 500/L or platelets of less than 20,000/L were observed. Patients younger than age 60 years who were randomly assigned to autologous SCT underwent collection of granulocyte colony-stimulating factor (G-CSF) -mobilized peripheral-blood stem cells, with at least 2 ϫ 10 6 /kg body weight CD34 ϩ cells considered an adequate recovery. Collection was done after the second course (HAM) in patients with less than 5% blasts in their bone marrow after the first course, and after the TAD consolidation course in patients with Ն 5% blasts after the first course. This compares with precollection consolidation courses in previous trials. [23] [24] [25] [26] After recovery from TAD consolidation, patients received busulfan/ cyclophosphamide conditioning (busulfan 41 mg/kg per day for 4 days orally on days Ϫ7 to Ϫ4, and cyclophosphamide 60 mg/kg/d IV infusion on days Ϫ3 and Ϫ2) before the autologous stem cells were reinfused. Effective methods of in vitro purging have been developed to avoid reinfusion of autologous leukemic cells. [27] [28] [29] However, adequate prospective investigations are lacking 30, 31 and purging was used in only one 26 of four previous trials. [23] [24] [25] [26] Thus, in vitro purging was not selected for this study protocol.
Independent of random assignment, younger patients with histocompatible family donors underwent allogeneic SCT in the first complete remission (CR). In a subtrial within the trial conducted at 32 of the 52 centers, patients were randomized upfront to G-CSF priming or no G-CSF. G-CSF was administered daily by subcutaneous injections of 150 g/m 2 from 48 hours before until the last dose of each chemotherapy course during the first year.
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Statistical Analyses
The primary objective of this trial was to compare the therapeutic effects of the two induction therapies TAD-HAM versus HAM-HAM, and (restricted to patients younger than age 60) to compare the effects of the two postremission therapies of prolonged maintenance versus autologous SCT. The comparisons in outcome were done for the total cohort of patients at all ages, for patients younger than 60 years and those Ն 60 years separately, and for defined prognostic groups within the age groups.
When each prognostic factor was considered, the groups were dichotomized into a more favorable and a more unfavorable prognostic subgroup. Regarding cytogenetics, the groups were subdivided into favorable, intermediate, and unfavorable karyotypes. Among the criteria of outcome, CR was defined by a cellular bone marrow with less than 5% blasts and a peripheral blood with at least 1,500/L absolute neutrophils and 100,000/L platelets, and persistent leukemia was defined by more than 5% blasts in the bone marrow after the complete induction treatment. Early or hypoplastic death was defined as death before 1 week from the end of the first induction course and later death in hypoplasia with less than 5% bone marrow blasts. SV was measured from treatment start to death. Remission duration (RD) was counted from achievement of CR until relapse, and RFS was counted from achievement of CR until relapse or death in CR. The response criteria essentially adhered to the recommendations of an international consensus. 21 The outcome was evaluated according to intention to treat. Significances were calculated for response rates by 2 test; for OS, SV, RFS, and RD by log-rank test; and for multivariate analyses by logistic and Cox regression. 
RESULTS
Patient Population
Between June 1999 and February 2005, a total of 1,795 patients entered onto the trial at the 52 participating centers; 25 patients were excluded because of medical contraindications (20 patients) or protocol violation (five patients). Characteristics of the 1,770 patients included are listed in Table 1 .
Drug Delivery
According to the protocol, 87% of patients younger than 60 years received two induction courses (88% in the TAD-HAM and 86% in the HAM-HAM arm). The reasons for not administering a second course were early death (8% and 8% in the two arms, respectively) and toxicity (4% and 6%, respectively). Among the patients Ն 60 years, 37% received two induction courses (41% in the TAD-HAM arm and 33% in the HAM-HAM arm; P ϭ .01). A second course was not administered to those older patients with 5% or more residual bone marrow blasts because of early death (5% and 4% in the two arms, respectively) or toxicity (11% and 15%, respectively). Among the patients younger than age 60 who were randomly assigned for the postremission therapy and achieved CR, 51% of those assigned to prolonged maintenance received maintenance treatment. The reasons for not receiving maintenance were relapse (8%), death in CR (4%), preferred autologous SCT (1%), planned SCT (2%), toxicity (3%), and refusal (1%) or unknown (11%).
Among those assigned to autologous SCT, 24% underwent this treatment. The reasons for not performing autologous SCT were relapse (13%), death in CR (2%), lack of sufficient stem cells mobilized and collected (12%), planned SCT (1%), toxicity (9%), and refusal (4%) or unknown (11%). In addition, the proportions of patients with allogeneic SCT in the maintenance and autologous SCT arm were 19% and 24% (P ϭ .19). Considering the entire patient group with CR distributed to two treatment arms, the present proportions of maintenance and autologous SCT compare well with calculations from previous trials. 
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Toxicity
There are no significant differences in severe adverse events between the two induction arms (Table 2) . Outcome by random assignment in patients with unfavorable karyotype. (A) Age younger than 60 years, overall survival by induction; (B) age younger than 60 years, remission duration by induction; (C) age younger than 60 years, overall survival by postremission treatment; (D) age younger than 60 years, remission duration by postremission treatment; (E) age Ն 60 years, overall survival by induction; and (F) age Ն 60 years, remission duration by induction. TAD, thioguanine, cytarabine, and daunorubicin; HAM, high-dose cytarabine and mitoxantrone; CR, complete remission; Auto SCT, autologous stem-cell transplantation.
age separately. The data of outcome are concordant between patients entering before and those entering after January 1, 2002. Of the older patients, 30% in the TAD-HAM arm and 36% in the HAM-HAM arm were in CR after the first course (P ϭ .049).
Outcome by Random Assignment for Postremission Treatment
The outcome in patients younger than age 60 who were initially randomly assigned to autologous SCT or prolonged maintenance and achieved a CR is shown in Figure 3 .
Because it was part of the protocol, allogeneic SCT in first CR remained uncensored. Allogeneic SCT when remaining uncensored, when being censored, or being excluded, resulted in median RFS of 22, 22, and 21 months with 41%, 40%, and 38% at 3 years, respectively and equally in both arms.
Outcome by Postremission Treatment Administered
The two randomly assigned arms were also evaluated selectively for patients who received at least one course of maintenance or underwent autologous SCT. There was again no difference in RD (50% v 44% at 3 years; P ϭ .31) and RFS (48% v 43% at 3 years; P ϭ .35). OS, however, showed an advantage for maintenance (71% v 53% at 3 years; P ϭ .005; Kaplan-Meier estimates not shown). The two treatments delivered were balanced for de novo and other AML and for cytogenetics.
Based on treatment administered, we also evaluated allogeneic SCT versus maintenance using a matched-pair system. In 98 of the 128 patients undergoing allogeneic SCT, a matched partner in the maintenance group could be identified concordant in age, cytogenetic group, de novo/secondary AML, and RFS achieved at the time of SCT. At 3 years, allogeneic SCT versus maintenance shows 77% v 46% Abbreviations: OS, overall survival; RD, remission duration; TAD, thioguanine, cytarabine, and daunorubicin; HAM, high-dose cytarabine and mitoxantrone; SCT, stem-cell transplantation; LDH, lactate dehydrogenase; BM, bone marrow; AML, acute myeloid leukemia; sAML, secondary acute myeloid leukemia; MDS, myelodysplastic syndrome.
patients relapse free (P ϭ .0007), and an OS of 56% v 60% (P ϭ .65; Kaplan-Meier estimates not shown). Table 3 lists a multivariate analysis of patient features independently predicting for outcome, in patients younger than 60 and those Ն 60 years of age.
Multivariate Analysis of Prognostic Factors
Outcome by Random Assignment in Prognostic Groups
As for younger and older patients (Fig 2) , other prognostic subgroups were analyzed for differences in therapeutic outcome between the randomly assigned arms (Fig 4; Tables 4 and 5 ). There is a general concordance in OS and RD between the randomly assigned arms. Only patients younger than 60 years with more than 40% bone marrow blasts after the first course show a trend to longer OS from maintenance in the log-rank test (P ϭ .044), and patients Ն 60 years with more than 700 U/L LDH show a trend to longer OS from HAM-HAM induction (P ϭ .024). In both cases, the projections to 3 years are concordant between the randomly assigned arms.
Outcome by Random Assignment for G-CSF Priming
A total of 895 patients entered the subtrial on G-CSF priming versus no G-CSF. As published before, 32 there was no difference in OS or RFS between the randomly assigned arms in any subgroup according to age, cytogenetics, LDH, and blast clearance.
DISCUSSION
Dose-response effects in AML have been reported for the induction as well as postremission period of therapy. [1] [2] [3] [4] [5] Remaining open questions currently discussed are whether further intensification of induction by additional high-dose cytarabine or myeloablative chemotherapy with autologous SCT can further improve the outcome, and how these effects are expressed in prognostic subgroups. The open questions are addressed here in 1,770 enrolled adult patients at all ages, with 53% older than 60 years of age, and diagnosed with de novo AML, AML secondary to cytotoxic treatment, AML secondary to MDS, and highrisk MDS.
Importantly, the more intensive induction regimen using two courses of HAM did not result in any change in outcome, such as response, persistent leukemia, and early death rate, or in OS, RD, and RFS. This finding in the entire population was seen equally in younger and in older patients. Although the patients older than 60 years received age-adapted treatment of 1 g/m 2 instead of 3 g/m 2 cytarabine and, if possible, only one induction course, the more intensive regimen HAM-HAM regimen did not compromise its tolerability and even tended to increase the CR rate after the first induction course. However, there were no significant benefits from the more intensive induction in the outcome for any prognostic subgroup such as secondary AML/MDS, cytogenetic groups, higher or lower levels in LDH, WBC, or day 16 residual bone marrow blasts. Unlike in postremission therapy 19 the dose-response to high-dose cytarabine administered here in induction therapy did not vary by cytogenetic groups. The equivalence in outcome from the two randomized induction regimens is remarkable considering the cytotoxicity actually delivered. Thus, TAD-HAM and HAM-HAM are calculated to differ by about a factor of 2 in their total dose of cytarabine within both the younger and the older patients.
Similar to the two induction treatments, the two different postremission strategies (autologous SCT and maintenance chemotherapy) did not result in different OS, RD, or RFS in the group of patients younger than age 60, in the only group randomly assigned for autologous SCT, or in any of their prognostic subgroups. Although the two randomly assigned arms were balanced for prognostic factors and for the two versions of induction treatment, there are certain imbalances in the delivery between the maintenance chemotherapy and the autologous SCT. Thus, autologous SCTs were abandoned if insufficient stem cells were collected (37 of 287 patients). In addition, contraindications against autologous SCT due to toxicity or refusal were more frequent (40 of 287 patients) than contraindications against maintenance treatment (12 of 277 patients). Finally, the decision for an allogeneic SCT was more frequent in the autologous SCT arm (74 of 287 patients) than in the maintenance arm (54 of 277 patients; P ϭ .075). However, if patients with allogeneic SCT are censored or excluded, there is no deviation from the uncensored analyses of OS, RD, and RFS. Although multicenter trial results on the relative value of autologous SCT are conflicting, [23] [24] [25] [26] 33 our prospective analysis based on intention to treat and avoiding dropouts of CR patients does not show a superiority of autologous SCT over prolonged chemotherapy. Beyond intention to treat, these findings are emphasized by the comparisons of the therapies administered, for which autologous SCT also exhibits the problem of inferior OS.
Allogeneic SCT as a priority option for patients with family donors could be evaluated by a matched-pair system and confirmed its high antileukemic potential by a superior freedom from relapse; however, this result was counterbalanced in the OS by a higher treatmentrelated death rate.
In a subtrial within this trial, 32 of the 52 participating centers addressed the question of whether the effect of antileukemic therapy can be augmented by the addition of G-CSF before and during each chemotherapy course administered in the first year of treatment. G-CSF was administered alone during 48 hours and together with cytarabine during an additional 48 hours before the administration of the S-phase toxic daunorubicin or mitoxantrone. There was no trend of a difference in OS, RD, or RFS according to the randomization for G-CSF priming or no G-CSF, as observed in a recent interim analysis of this issue. 32 The results of G-CSF priming presented by the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) group 34 thus could not be reproduced (to date) in the setting of high-dose cytarabine induction.
On the basis of two cytarabine/anthracycline induction courses (one of them containing high-dose cytarabine) combined with prolonged maintenance, patient outcome is not improved by a second high-dose induction course and myeloablative treatment with autologous SCT. Once a certain treatment intensity has been reached, the antileukemic potential may be exhausted and not augmented by additional intensification. A more promising approach may be provided by allogeneic SCT when its high antileukemic potential is combined with a reduced transplantation-related death rate. 35 It will take another 2 to 3 years of observation to detect potential effects of treatment alternatives in smaller subgroups of patients. This preliminary analysis may be helpful to other groups for designing new protocols based on different induction and postremission strategies.
